Somatostatin receptor expression and occupancy during lanreotide therapy

Recruiting

• Conditions: hormone producing tumor; Neuroendocrine tumor; 10014713

• Registration Number: NL-OMON53159
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 34

Inclusion Criteria

- >=18 years old
- Histologically confirmed low and intermediate grade NET
- Metastatic or unresectable disease
- Measurable disease on [68Ga]-DOTATATE PET-scan
- WHO performance status less than 2
- Life expectancy more than 3 months
- Long-acting lanreotide treatment for at least 4 months

Exclusion Criteria

- Pregnant or breast-feeding
- Claustrophobic

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To visualize and quantify the difference in somatostatin receptor occupancy<br /><br>directly before and after lanreotide injection.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>a. To assess a correlation between tumor [68Ga]-DOTATATE uptake and size in<br /><br>relation to lanreotide binding.<br /><br>b. To assess differences in [Ga68]-DOTATATE uptake and behavior (reaction to<br /><br>lanreotide) between different metastasis in 1 patient.<br /><br>c. To assess the differences in uptake in normal tissue (thyroid, spleen, liver<br /><br>etc.) before and after lanreotide.<br /><br>d. To assess the correlation between clinical symptoms, receptor occupancy, and<br /><br>tumor markers. </p><br>